AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS

Their core work

AEMPS is Spain's national medicines regulatory agency, responsible for authorizing and supervising medicines and medical devices on the Spanish market. In H2020, they contribute regulatory expertise to European health data initiatives — particularly around drug identification standards (IDMP), pharmacovigilance, and cross-border eHealth interoperability. They also participate in large-scale hematology/oncology data platforms (HARMONY) and patient-facing digital health tools, bringing the regulator's perspective on safety, standardisation, and risk minimisation to multi-country consortia.

What they specialise in

How they've shifted over time

AEMPS entered H2020 through clinical data platforms, joining HARMONY (2017) to pool real-world patient data on leukemia, lymphoma, and other hematological cancers. From 2019 onward, their focus shifted decisively toward regulatory infrastructure: drug database standardisation (UNICOM/IDMP), regulatory science capacity building (STARS), and cross-border eHealth interoperability. Their most recent project (Gravitate-Health, 2020) signals a further pivot toward patient-facing digital tools for medication self-management.

AEMPS is moving from passive data contributor toward active involvement in European digital health infrastructure and regulatory harmonisation — expect continued focus on IDMP implementation, cross-border prescription systems, and patient empowerment tools.

How they like to work

AEMPS participates exclusively as a partner, never as coordinator — consistent with their role as a national regulatory body contributing domain authority rather than managing research projects. They operate in large consortia (149 unique partners across 7 projects), which reflects the multi-country regulatory harmonisation nature of their work. Their value in a consortium is institutional: they bring the weight and data access of a national medicines agency, not a research lab.

AEMPS has collaborated with 149 unique partners across 26 countries, reflecting broad pan-European reach typical of regulatory harmonisation projects. Their network spans fellow national agencies, EMA, pharmaceutical industry (via IMI2), hospitals, and health IT organisations.

What sets them apart

AEMPS is one of Europe's major national medicines agencies, and their H2020 participation gives consortium partners direct access to a regulatory authority's perspective and data. Unlike university partners who bring research capacity, AEMPS brings regulatory legitimacy, access to national pharmacovigilance databases, and practical insight into how new health standards will actually be implemented. For any project touching drug safety, medicine identification, or cross-border health services, having a national regulator at the table strengthens both the work and the credibility of results.

Highlights from their portfolio

• UNICOM
  By far their largest project (EUR 910K of EUR 1.45M total funding), focused on scaling global medicine identification standards (IDMP) — directly tied to AEMPS's core regulatory mandate.
• HARMONY
  Major IMI2 public-private partnership building Europe's largest hematology big data platform with real-world patient data across multiple blood cancer types.
• Gravitate-Health
  Their most recent and longest-running project (2020-2026), signalling a strategic shift toward patient-facing digital health and medication self-management tools.